About
Tallac Therapeutics™ is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.
Tallac team

Michael Chang
Associate Director,
CMC

Stacy Fide
Associate Director,
Study Management

Ons Harrabi
Associate Director,
Clinical Biomarkers

Josh Lee
Associate Director,
Clinical Operations

Mingrui An
Principal Scientist

Maja Bonacorsi
Principal Scientist

Amy Chen
Principal Scientist

Emma Sangalang
Principal Scientist

Tiffany Chou
Scientist

Danielle Fontaine
Scientific Associate II

Erica Belkin
Associate Lab Manager

Verwina Roble
Sr. Accountant / Office Manager